PITTSBURGH, Dec. 18, 2013 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL) today announced that it has received all regulatory approvals and has completed an agreement with Pfizer for the exclusive worldwide rights to develop, manufacture and commercialize a novel long-acting muscarinic antagonist (LAMA) compound for various indications. Mylan expects that this product, which is ready to […]
Captures Five Optical Measurements in One High-Resolution Scan; Same Wavefront Sensing Technology Used to Measure NASA’s James Webb Space Telescope’s Optics December 17, 2013 — Abbott Park, Illinois (NYSE: ABT) — With the introduction of Abbott’s iDesign Dx system, U.S. ophthalmologists now have a diagnostic tool that can capture five optical measurements in one three-second […]
– Biogen Idec Opts-In to Commercialization Opportunity with Joint Venture Partner – CAMBRIDGE, Mass. & SEOUL, Korea–(December 17, 2013)–Biogen Idec (NASDAQ: BIIB) and Samsung Bioepis today announced that through their joint venture, Biogen Idec has exercised its right to enter into an agreement to commercialize anti-TNF biosimilar product candidates in Europe, including biosimilars for widely used therapies to […]
Agreement includes a no-later-than July 9, 2015 launch PITTSBURGH, Dec. 17, 2013 /PRNewswire/ — Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. and partner, Banner Pharmacaps Inc. (a wholly-owned subsidiary of Patheon Inc.), have entered into a settlement and license agreement with Eisai Inc. and Valeant Pharmaceuticals Luxembourg S.a.r.l that will […]
Walgreens and CDC to Evaluate HIV Care Model at More Than 700 HIV-Specialized Pharmacies DEERFIELD, Ill., December 16, 2013 – In support of the more than 1.1 million people living with HIV in the U.S., Walgreens (NYSE: WAG) (Nasdaq: WAG) is collaborating with the Centers for Disease Control and Prevention (CDC) to develop and evaluate […]
– Sovaldi Receives Marketing Authorization for Patients with Genotypes 1, 2, 3 or 4 HCV – – High Cure Rates (SVR 12) and Therapy Shortened to Just 12 Weeks for Many Patients – FOSTER CITY, Calif.–(BUSINESS WIRE)–Dec. 16, 2013– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Health Canada has issued a Notice of Compliance for Sovaldi™ (sofosbuvir) 400 […]
PALO ALTO, Calif., Dec. 16, 2013 /PRNewswire/ — Varian Medical Systems (NYSE:VAR) today announced that Robert H. Kluge has announced his intention to retire as its Senior Vice President and President, Imaging Components Businesses effective February 7, 2014. Varian CEO Dow R. Wilson has named and the Board of Directors has appointed Sunny Sanyal, CEO of T-System, to succeed Kluge. Varian’s Imaging Components Businesses […]
Combination Creates a Global Leader in Aesthetics Transaction Values Solta at Approximately $250 Million Transaction Expected to Close in the First Quarter of 2014 LAVAL, Quebec and HAYWARD, Calif., Dec. 16, 2013 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that it has entered into a definitive agreement under which […]
MALVERN, Pa., Dec. 16, 2013 /PRNewswire/ — Accretive transaction furthers Endo’s transformation into leading specialty healthcare company Builds on Endo’s leadership in pain management through addition of ZECUITY® (sumatriptan iontophoretic transdermal system), the first and only FDA approved patch to treat migraine Proven Endo branded pharmaceuticals commercial team to execute ZECUITY launch, expected in first half 2014 Endo […]
— European Commission Also Approves Expanded Indication for Regimen, Marketed as Eviplera® in the European Union — FOSTER CITY, Calif.–(BUSINESS WIRE)–Dec. 13, 2013– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the single tablet HIV-1 regimen Complera® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA <50 copies/mL) adult patients on a stable […]